Kymera Therapeutics (KYMR) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Kymera Therapeutics (KYMR) quarterly earnings & revenue
Kymera Therapeutics (KYMR) reported revenue of $34.37M for Q1 2026, up 55.5% year-over-year, with net income of $-69.23M and diluted EPS of $-0.71.
Over the last four reported quarters, Kymera Therapeutics generated $51.47M in revenue and $-315.05M in net income.
Kymera Therapeutics's next earnings report is scheduled for August 10, 2026 before market open; analysts estimate EPS of $-0.72.
Kymera Therapeutics quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $34.37M | +55.5% | $-69.23M | $-0.71 |
| Q4 2025 | $2.86M | -61.3% | $-87.03M | $-0.98 |
| Q3 2025 | $2.76M | -26.1% | $-82.17M | $-0.94 |
| Q2 2025 | $11.48M | -55.3% | $-76.61M | $-0.95 |
| Q1 2025 | $22.10M | +114.8% | $-65.58M | $-0.82 |
| Q4 2024 | $7.39M | -84.6% | $-70.75M | $-0.88 |
| Q3 2024 | $3.74M | -20.9% | $-62.49M | $-0.82 |
| Q2 2024 | $25.65M | +55.3% | $-42.06M | $-0.58 |
Kymera Therapeutics (KYMR) — frequently asked questions
When does Kymera Therapeutics (KYMR) report earnings next?
Kymera Therapeutics is expected to report earnings on August 10, 2026 before market open. Analysts estimate EPS of $-0.72.
What was KYMR's revenue last quarter?
Kymera Therapeutics reported revenue of $34.37M in Q1 2026, up 55.5% from the same quarter a year earlier.
What was KYMR's EPS last quarter?
Kymera Therapeutics reported diluted EPS of $-0.71 in Q1 2026.
Is Kymera Therapeutics profitable?
Kymera Therapeutics is currently not profitable, with $-315.05M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)